ArticleAACE endocrinology and diabetes
Differentiated Thyroid Cancer in Severe Insulin Resistance.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recombinant human thyrotropin reducing insulin resistance in patients with differentiated thyroid cancer.Journal of the Endocrine Society · 2026Article
- Metabolic crosstalk between differentiated thyroid cancer and cardiovascular disease: insulin resistance as a molecular bridge-a proposed mechanism.Frontiers in endocrinology · 2026Review
- Inflammation-Insulin Resistance Crosstalk and the Central Role of Myokines.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Hyperinsulinemia and insulin resistance (IR) are associated with increased cancer risk. Patients with severe IR due to lipodystrophy or mutations of the insulin receptor have increased thyroid nodule prevalence at young ages, and papillary thyroid cancer (PTC) has occurred. We describe thyroid cancer cases in severe IR and analyze prevalence and clinical and pathologic features of PTC in cohorts with severe IR, mild IR, and euglycemic controls. Methods: PTC prevalence in severe IR was compared with SEER database population data. Cross-sectional comparison was performed in 70 patients with PTC (6 severe IR, 13 type 2 diabetes, and 51 controls). Main outcome measure(s) were PTC prevalence, tumor characteristics, and immunohistochemistry. Results: PTC prevalence in severe IR was 2.2% versus 0.29% based on SEER data for the US population ( Conclusion: This study suggests that severe IR syndromes are associated with increased PTC risk. However, there were no differences in PTC characteristics between groups with varying degrees of IR. Mechanisms linking severe IR with PTC development require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.